There are currently 119 active clinical trials seeking participants for Pancreatic Cancer research studies. The states with the highest number of trials for Pancreatic Cancer participants are California, New York, Illinois and Texas.
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT06973161
Recruiting
In DESTINY-Pan-Tumor \[DP-02\], DESTINY CRC02 \[DC-02\], and DESTINY-Lung01 \[DL-01\], T-DXd demonstrated tumor response across a broad range of HER2-expressing solid tumors, particularly IHC3+ patients. This study will use real-world data (RWD) to identify IHC3+ patients in the real world who received standard of care (SoC) and compare them with IHC3+ patients who received T-DXd in the referent trials. The tumors included are: non-small cell lung cancer \[NSCLC\], colorectal cancer \[CRC\], en... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/14/2025
Locations: Research Site, Spartanburg, South Carolina +26 locations
Conditions: Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Other Tumors
Register for Updates
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
NCT06168812
Recruiting
The purpose of this study is to find out how effective and safe glipizide is for lowering blood sugar in people with pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Metastatic, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771
Recruiting
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center, La Jolla, California +17 locations
Conditions: Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer, KRAS G12C, Pancreatic Cancer
Register for Updates
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NCT06698458
Recruiting
This is a multi-center clinical study enrolling up to 30 participants (15 patients in each cohort). The primary objective of the study is to evaluate the safety of Alpha DaRT in combination with chemotherapy, based on the cumulative incidence rate, severity and outcome of device related AEs. Classification of AEs will be done according to CTCAE V5. The secondary objectives of the study are to: * Assess efficacy of the Alpha DaRT sources in combination with chemotherapy, determined by overall an... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/13/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +15 locations
Conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Register for Updates
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
NCT05836870
Recruiting
To learn if a supervised exercise program during chemotherapy treatments can help to improve outcomes in patients who have been diagnosed with pancreatic cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Pancreatic Cancer
Register for Updates
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845
Recruiting
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona +20 locations
Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
Register for Updates
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
NCT06298916
Recruiting
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).
Gender:
ALL
Ages:
15 years and above
Trial Updated:
08/06/2025
Locations: City of Hope, Duarte, California +4 locations
Conditions: Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
Register for Updates
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
NCT06941857
Recruiting
The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
NCT02361320
Recruiting
This trial studies how well computed tomography works in diagnosing patients with pancreatic or hepatobiliary cancer. Computed tomography may help researchers predict how patients with pancreatic or hepatobiliary cancer may respond to chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Pancreatic Cancer
Register for Updates
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
NCT04751435
Recruiting
Genetic testing is a type of test that detects changes to the genes-the DNA instructions that are passed on from the mother and father. The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Genetic testing can also help determine a person's chance of getting or passing on a genetic disorder. Genetic tests use a sample of blood, hair, skin, or other tissue, and they can look at one gene or m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Kings County Hopsital Center, Brooklyn, New York +3 locations
Conditions: Educational Materials for Genetic Testing, Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer
Register for Updates
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
NCT03334708
Recruiting
The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey +12 locations
Conditions: Pancreatic Cancer, Pancreatic Diseases, Pancreatitis, Pancreatic Cyst
Register for Updates
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
NCT06205849
Recruiting
This is a phase I study of an agonistic CD40 antibody (mitazalimab) injected intratumorally at the time of surgical IRE in patients with locally advanced pancreatic cancer. Intratumoral delivery has potential to be more effective than systemic (intravenous) delivery while decreasing the systemic side effects of immunotherapy. We hypothesize that local delivery of mitazalimab at the time of IRE in patients with locally advanced pancreatic cancer will be safe, augment the immune effects of IRE, an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: UCSD Moores Cancer Center, La Jolla, California
Conditions: Pancreatic Cancer
Register for Updates